A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF AZACITIDINE SUBCUTANEOUS IN COMBINATION WITH DURVALUMAB (MEDI4736) IN PREVIOUSLY UNTREATED SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR IN ELDERLY (>/= 65 YEARS) ACUTE MYELOID LEUKEMIA (AML) SUBJECTS NOT ELIGIBLE OR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
The goal of this clinical research study is to learn if adding durvalumab to azacitidine can help to control AML and/or MDS. The safety of this drug combination will also be studied. You are being asked to take part in this study because you have either acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Treatment Location: N/A
IRB Review and Approval Date: 12/14/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: